Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease
Open Access
- 28 April 2026
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (8) , e214804
Abstract
Cognitive reserve has been shown to modulate the onset and progression of Alzheimer disease (AD) symptoms. Although its role in sporadic AD is well-studied, how cognitive reserve influences the timing and progression of symptoms in dominantly inherited AD (DIAD) remains unclear. This study aimed to quantify cognitive reserve in DIAD carriers and test whether higher cognitive reserve is associated with later symptom onset and slower functional decline. We analyzed data from the Dominantly Inherited Alzheimer's Network study. Cognitive reserve was modeled using a residual-based latent variable approach, decomposing cognitive performance into demographic (CogD), biomarker (CogB), and reserve or residual (CogR) components. Primary outcomes were age at clinical symptom onset (CDR >0) and longitudinal change in the Clinical Dementia Rating-Sum of Boxes (CDR-SBs). Data were analyzed using Cox proportional hazards models and linear mixed-effects models, adjusting for estimated years from onset (EYO). A total of 710 Dominantly Inherited Alzheimer Network (DIAN) participants were included in the analysis, comprising 271 non-DIAD carriers (nMC), 284 asymptomatic DIAD carriers (aMC), and 155 symptomatic DIAD carriers. In asymptomatic carriers, using a zero-inflation model adjusted for EYO showed that a 1 SD increase in the reserve component (CogR) was associated with a 4.06-fold increase in the odds of being clinically unimpaired (CDR-SB = 0; 95% CI 1.84-8.95). Similarly, a 1 SD increase in the demographic (CogD) and biomarker (CogB) components increased the odds of being CDR-SB = 0 by 2.60 (95% CI 1.10-6.16) and 5.16 (95% CI 2.00-13.33), respectively. Among symptomatic carriers, only the reserve and the biomarker components were significant. A 1 SD increase in CogR was associated with a 0.81-fold reduction in baseline CDR-SB score (95% CI 0.72-0.92), and a 1 SD increase in CogB was associated with a 0.60-fold reduction in CDR-SB (95% CI 0.50-0.71). Our findings indicate that higher cognitive reserve values are associated with delayed conversion to mild cognitive impairment and slower progression on clinical dementia rating scales. These findings suggest that cognitive reserve plays a protective role in modifying the clinical trajectory of genetically determined AD.Keywords
This publication has 44 references indexed in Scilit:
- Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer NetworkAlzheimer's & Dementia, 2023
- Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementiaActa Neuropathologica, 2022
- Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degenerationAlzheimer's & Dementia, 2020
- Association of Lifestyle and Genetic Risk With Incidence of DementiaJAMA, 2019
- Untangling Genetic Risk for Alzheimer’s DiseaseBiological Psychiatry, 2018
- The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelAlzheimer's & Dementia, 2016
- Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment StrategiesCurrent Neurology and Neuroscience Reports, 2014
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque PathologyArchives of Neurology, 2011
- Variability of Age at Onset in Siblings With Familial Alzheimer DiseaseArchives of Neurology, 2007
- Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutationAnnals of Neurology, 2007